Novo Nordisk reports Phase II data for zenagamtide in diabetes

Novo Nordisk has reported results from its Phase II study of zenagamtide, showing drops in blood sugar and body weight among T2D adults compared to placebo. The primary endpoint, change in HbA1C after 36 weeks, was met at all doses. Novo Nordisk will advance zenagamtide to Phase III trials for adults with type 2 diabetes in H2 2026. Credit: Andrzej Rostek / Shutterstock.com. Novo Nordisk has reported results from its Phase II study of zenagamtide, an investigational once-weekly subcutaneous treatment, showing statistically significant reductions in blood sugar and body weight among adults with type 2 diabetes (T2D) compared to placebo.…

Source: Clinical Trials Arena